Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00138
2010-06-04
Retrospective
Nil
RGC funding for the study
RGC funding
Nil
Cheuk Man Yu
Rm. 12A28, 12/F, Main Building, PWH
2632 1752
cmyu@cuhk.edu.hk / poonsps@yahoo.com.hk
Nil
Cheuk Man Yu
Rm. 12A28, 12/F, Main Building, PWH
2632 1752
cmyu@cuhk.edu.hk / poonsp@cuhk.edu.hk
Nil
Serial Echocardiographic Assessment of Early Right Ventricular Dysfunction by Tissue Doppler Echocardiography & its Impact on Left Ventricular Function
Serial Echocardiographic Assessment of Early Right Ventricular Dysfunction by Tissue Doppler Echocardiography & its Impact on Left Ventricular Function
利用組織多普勒超聲波, 對早期的右心室功能不全, 以及其對左心室功能的影響, 進行一系列的超聲波評估
Nil
Hong Kong
Yes
2006-02-07
Chronic obstructive pulmonary disease (COPD)
Procedure
Serial Echocardiographic examine the effect of Chronic Obstructive Pulmonary Disease of Early Right Ventricular Dysfunction
5 years
The goal of the proposed research project is to examine the effect of chronic obstructive pulmonary disease (COPD) on early occurrence of right ventricular [RV] dysfunction in both systole and diastole independent of development of hypertension, and its impact on left ventricular [LV] function. This can be achieved by the use of a sensitive echocardiographic tools, namely tissue Doppler imaging (TDI) and 3-dimensional echocardiography (3DE).
1). Patients diagnosed with COPD who are stable (without history of acute exacerbation of COPD in the past 3 months before enrolment), and,
2). Objective evidence of abnormal and obstructive lung function by spirometry, with FEV1 between 30-80% of normal age-predicted value and FEV1/FVC ratio <70%.
1). COPD with history of hospitalization due to acute exacerbation within the past 3 months
2). COPD who are dependent on assisted ventilation of any kind that may affect cardiac function
3). Patients who have other interstitial lung disease, e.g. pneumoconiosis, bronchiectasis, alveolar fibrosis, etc
4). Patients with other active lung pathologies, such as primary or secondary lung malignancies, pneumonia, active tuberculosis, pleural effusion, etc
5). Patients with primary pulmonary hypertension
6). Patients with secondary pulmonary hypertension other than due to COPD, such as thromboembolism
7). Patients who known structural heart disease, such as coronary heart disease, left ventricular hypertrophy, significant valvular heart disease, cardiomyopathies, etc
8). Patients with active cardiac arrhythmias such as atrial fibrillation
9). Patients with active systemic illness or end-organ disease that may affect cardiac or pulmonary function, such as renal or liver failure
10). Patients with disease with expected life expectancy <1 year, such as malignancies
11). Patients who refuse to participate the study
> 18 years of age
Patient > 18 years of age
Both Male and Female
Observational
Non-randomized
Active
Open label
Parallel
2006-03-27
150 patien
Complete
Patients enrolled into the study will perform baseline assessment that include spirometry with DLCO, ECG, echo (with TDI and 3DE) examination, 6-Minute hall walk test, quality of life by St. Georges Respiratory Questionnaire, and blood test for neurohormones (B-type natriuretic peptides [BNP]), N-terminal Pro-BNP, epinephrine and norepinephrine). The investigation data collected from the Cross-sectional study will also be used as the baseline tests for the Prospective study. Patients will then be followed by regularly by the respiratory physicians in the outpatient specialist clinic of the hospital at regular intervals for a total duration of 12 months. The occurrence of major events including hospitalization of acute COPD will be monitored. During follow-up, investigations will be performed to examine for the changes in cardiac and lung functions, clinical status, quality of life and neurohormonal levels. As subjects enrolled into the study are stable COPD patients, change of regular medications are discouraged unless clinically indicated.
Nil
2014-01-29
ChiCTR-ONRC-10000909
2010-06-04
Yes
Nil
|
|
|
|
|
---|---|---|---|---|
No documents yet. |